LSV Asset Management Sells 26,100 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

LSV Asset Management reduced its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 4.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 590,700 shares of the company's stock after selling 26,100 shares during the period. LSV Asset Management owned about 1.19% of Prestige Consumer Healthcare worth $36,163,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1.8% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 10,068 shares of the company's stock valued at $576,000 after purchasing an additional 179 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 85.7% in the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company's stock valued at $27,000 after purchasing an additional 204 shares during the last quarter. M&T Bank Corp lifted its holdings in shares of Prestige Consumer Healthcare by 7.5% during the 4th quarter. M&T Bank Corp now owns 4,139 shares of the company's stock valued at $253,000 after acquiring an additional 289 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Prestige Consumer Healthcare by 0.4% during the 3rd quarter. Raymond James & Associates now owns 96,433 shares of the company's stock valued at $5,515,000 after acquiring an additional 394 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $25,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Up 0.0 %

PBH stock traded up $0.02 during trading on Monday, reaching $70.02. The stock had a trading volume of 190,274 shares, compared to its average volume of 234,840. Prestige Consumer Healthcare Inc. has a 1-year low of $55.96 and a 1-year high of $75.31. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $3.48 billion, a P/E ratio of -42.69, a PEG ratio of 1.90 and a beta of 0.53. The firm has a fifty day moving average price of $71.12 and a 200 day moving average price of $64.73.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The firm had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. During the same quarter in the previous year, the business posted $1.04 EPS. The firm's revenue was up 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.33 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 5,336 shares of the business's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the sale, the senior vice president now owns 15,934 shares of the company's stock, valued at approximately $1,099,446. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PBH shares. TheStreet upgraded shares of Prestige Consumer Healthcare from a "c+" rating to a "b-" rating in a report on Monday, February 12th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, February 10th. One research analyst has rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.00.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.